Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin

作者：Robach Paul; Recalcati Stefania; Girelli Domenico; Gelfi Cecilia; Aachmann Andersen Niels J; Thomsen Jonas J; Norgaard Anne M; Alberghini Alessandra; Campostrini Natascia; Castagna Annalisa; Vigano Agnese; Santambrogio Paolo; Kempf Tibor; Wollert Kai C; Moutereau Stephane; Lundby Carsten; Cairo Gaetano^*

来源：Blood, 2009, 113(26): 6707-6715.

DOI：10.1182/blood-2008-09-178095

The high iron demand associated with enhanced erythropoiesis during high-altitude hypoxia leads to skeletal muscle iron mobilization and decrease in myoglobin protein levels. To investigate the effect of enhanced erythropoiesis on systemic and muscle iron metabolism under nonhypoxic conditions, 8 healthy volunteers were treated with recombinant erythropoietin (rhEpo) for 1 month. As expected, the treatment efficiently increased erythropoiesis and stimulated bone marrow iron use. It was also associated with a prompt and considerable decrease in urinary hepcidin and a slight transient increase in GDF-15. The increased iron use and reduced hepcidin levels suggested increased iron mobilization, but the treatment was associated with increased muscle iron and L ferritin levels. The muscle expression of transferrin receptor and ferroportin was upregulated by rhEpo administration, whereas no appreciable change in myoglobin levels was observed, which suggests unaltered muscle oxygen homeostasis. In conclusion, under rhEpo stimulation, the changes in the expression of muscle iron proteins indicate the occurrence of skeletal muscle iron accumulation despite the remarkable hepcidin suppression that may be mediated by several factors, such as rhEpo or decreased transferrin saturation or both. (Blood. 2009;113:6707-6715)

• 出版日期2009-6-25